Form 4: Stoke Therapeutics' Chief Medical Officer Sells Shares to Cover Tax Obligations, Acquires Stock Options and Restricted Stock Units

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, sold shares to cover tax liabilities while also acquiring stock options and restricted stock units.

Summary

• On March 18 and 19, 2025, Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, sold shares of common stock to satisfy tax withholding liabilities related to the vesting of restricted stock units.
• He sold 3,884 shares at a weighted average price of $8.67 on March 18, 2025, and 3,333 shares at a weighted average price of $8.27 on March 19, 2025.
• Following these transactions, Ticho still beneficially owns 60,629 shares of Stoke Therapeutics common stock.
• On March 20, 2025, Ticho acquired 64,000 employee stock options with an exercise price of $8.33, vesting monthly starting April 15, 2025, and expiring on March 19, 2035.
• He also acquired 43,000 restricted stock units (RSUs) that vest annually beginning on March 15, 2026, representing a contingent right to receive one share of common stock per RSU upon settlement.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The sale of shares is offset by the acquisition of stock options and RSUs, indicating continued commitment from the executive. The transactions appear to be routine and related to compensation.

Positives

• The acquisition of 64,000 employee stock options indicates confidence in the company's future performance.
• The grant of 43,000 restricted stock units (RSUs) aligns the executive's interests with those of the shareholders.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors.

Risks

• The vesting of stock options and RSUs is contingent upon continued service to the issuer, creating a potential risk if the executive leaves the company.
• Market fluctuations could impact the value of the shares and the exercisability of the stock options.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the stock options and RSUs suggest a long-term commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the biotechnology industry to incentivize executives and align their interests with shareholders.
• The vesting schedules and exercise prices are typical for similar companies in the sector.
• Comparing the size of the grants to those of executives at comparable companies like Sarepta Therapeutics or Biogen would provide further context.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but the overall impact is likely to be minimal.
• The granting of stock options and RSUs incentivizes the executive to work towards the long-term success of the company, benefiting all stakeholders.

Key Dates

Keywords

Stoke Therapeutics, Barry Ticho, Chief Medical Officer, Stock Options, Restricted Stock Units, Form 4, SEC Filing, Insider Trading, Share Sale, Beneficial Ownership